A Phase 2 Study of ABSK043 Combined With Osimertinib

NCT07710612 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive

Interventions

DRUG: ABSK043 in combination with Osimertinib

Sponsor

Abbisko Therapeutics Co, Ltd

Collaborators

[object Object]